Sir, Collins and Sheridan (1985; 53: 488-92) reported that compared with placebo treatment the alpha blocker indoramin (given three times a day) improved exercise tolerance and increased oxygen consumption during exercise in patients with stable angina pectoris. These results are different-from those reported by us.' We studied patients with stable angina pectoris who were not taking any other antianginal drugs. In a randomised crossover study we compared the effects of single doses of 50 and 75 mg indoramin with those of placebo. Exercise time to the onset of angina in seconds before and after placebo and before and after 50 This letter was shown to the authors, who reply as follows: Sir, We have difficulty in accepting that the failure of Thadani and Parker to find an improvement in exercise performance with indoramin (based on the results presented in their comments to this journal and in the abstract cited'), necessarily represents the demonstration of a different response to that reported by ourselves (1985; 53: 488-92) . This is because there are serious problems in the design of their study that could readily mask an improvement in response to the drug. For example there appears to have been an appreciable training effect (as indicated by the data obtained in their placebo group) and each subject received only one dose of indoramin, which, given its high first pass clearance,. is unsuitable for this type of study. We believe that with such difficulties a study based on nine patients is almost certainly inadequate. Furthermore, the exercise durations they observed at one hour after treatment appear to have increased approximately 30% after active treatment, compared with 1% after placebo treatment, based on the means presented. For these reasons, we believe that an interpretation of their results as indicating a negative response to the drug could well be misleading.
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